Communiqué Archives - Page 4 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
Urinary Steroid Profile [Test in Focus] - Insights
Irina Bancos, M.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken...
Learn why liquid biopsy testing is a viable alternative to tissue-based biopsy testing for certain patients with cancer.
T-cell Lymphoma [Test in Focus] - Insights
Andrew Feldman, M.D., discusses the different tools and techniques Mayo Clinic Laboratories uses to accurately diagnose and classify T-cell lymphomas to help provide clinicians with the diagnostic answers they need to treat their patients.
Disease-specific panels - Insights
Learn how disease-specific cancer panels help providers understand their patients’ risk of having a hereditary cancer syndrome.
Hereditary Colon Cancer Testing - Mayo Clinic Laboratories
Our algorithmic approach aids with the ordering process and guides physicians to ensure the right tests are being ordered at the right time for patients.
See how our comprehensive fluorescence in situ hybridization panels simplify the ordering process to ensure every patient receives the right test.
Children's Oncology Group - Insights
Learn how our team’s commitment and large testing menu helps in meeting the specific needs of Children’s Oncology Group patients.
Rapid hereditary breast cancer - Insights
Learn how our rapid breast cancer treatment panel delivers results in 10 to 14 days and detects 11 genes linked to lifetime breast cancer risk.